We are committed to doing what is right for our Associates and the customers and communities who rely on our products. Read a message from Gore’s Enterprise Leadership Team to learn more about our efforts.
Featured Story
As smartphone usage increases, consumer attitudes are changing to demand more protection.
Posted May 11, 2020
Gore research shows that water incidents with smartphones is common (42% in the last year) and when incidents occur most consumers (81%) have a bad outcome (35% malfunction, 46% inoperable). This translates to 34% of households having a negative experience with their smartphones in the last year and 19% having to replace their smartphone.
Failure-Free Protection & Performance
Operating Instructions: GORE Protein Capture Device for Early Clinical Applications, 9.0mL (PROA103)
Technical Information, 144.07 KB
General handling, antibody purification protocol and troubleshooting guide for PROA103.
Validation Guide: GORE Protein Capture Device for Early Clinical Applications, 9.0mL (PROA103)
Validation Guides
This unique membrane Device offered in 9.0 mL has a capacity of ≥ 360 mg when using 1.25 mg/mL human polyclonal hIgG in phosphate-buffered solution at 30 seconds residence time (SRT). Request the Validation Guide for complete testing details.
This document is available upon request.
Data Sheet: GORE Protein Capture Device for Early Clinical Applications, 9.0mL (PROA103)
Data Sheets, 230.71 KB
The 9.0mL Device (PROA103) GORE Protein Capture Device provides performance advantages over traditional agarose resin columns in late stage discovery, pre-clinical and early clinical applications.